# EDGAR Filing Document

**Accession Number:** 0001089815
**File Stem:** 0001437749-25-026553
**Filing Date:** 2025-8
**Character Count:** 73240
**Document Hash:** fd3a139e4806a1239e5bf898905d41b1
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001437749-25-026553.hdr.sgml**: 20250813

**ACCESSION NUMBER**: 0001437749-25-026553

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 47

**CONFORMED PERIOD OF REPORT**: 20250630

**FILED AS OF DATE**: 20250813

**DATE AS OF CHANGE**: 20250813

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Elite Health Systems Inc.
- **CENTRAL INDEX KEY:** 0001089815
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-SPECIALTY OUTPATIENT FACILITIES, NEC [8093]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 521842411
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-26575
- **FILM NUMBER:** 251212454

**BUSINESS ADDRESS:**
- **STREET 1:** 1131 W 6TH STREET
- **STREET 2:** SUITE 225
- **CITY:** ONTARIO
- **STATE:** CA
- **ZIP:** 91762
- **BUSINESS PHONE:** 949-249-1170

**MAIL ADDRESS:**
- **STREET 1:** 1131 W 6TH STREET
- **STREET 2:** SUITE 225
- **CITY:** ONTARIO
- **STATE:** CA
- **ZIP:** 91762

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Elite Health Systems, Inc.
- **DATE OF NAME CHANGE:** 20241002

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** U.S. NeuroSurgical Holdings, Inc.
- **DATE OF NAME CHANGE:** 20150828

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** US NEUROSURGICAL INC
- **DATE OF NAME CHANGE:** 19990630

?xml version='1.0' encoding='ASCII'? usnu20250630_10q.htm

[**Table of Contents**](#toc)

**<u>UNITED STATES</u>**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 10-Q**

**☒** QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

**For the quarterly period ended June 30, 2025**

or

**☐** TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT

For the transition period from to .

Commission file number: 0-15586

**Elite Health Systems Inc.**

(Exact name of registrant as specified in its charter)

---

| | |
|:---|:---|
| **Delaware** | **47-5370333** |
| (State or other jurisdiction of | (I.R.S. Employer |
| incorporation or organization) | Identification No.) |

---

**1131 W 6th Street, Ontario, CA 91762**

(Address of principal executive offices)

**(949) 249-1170**

(Registrant's telephone number)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.&nbsp;&nbsp;&nbsp;&nbsp; Yes ☒&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Section 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&nbsp;&nbsp;&nbsp;&nbsp; Yes ☒&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company, and "emerging growth company" in Rule 12b-2 of the Exchange Act. (Check one):

---

| | |
|:---|:---|
| Large accelerated filer&nbsp;&nbsp;&nbsp;&nbsp; ☐ | Accelerated filer&nbsp;&nbsp;&nbsp;&nbsp; ☐ |
| Non-accelerated filer&nbsp;&nbsp;&nbsp;&nbsp; ☒ | Smaller reporting company&nbsp;&nbsp;&nbsp;&nbsp; ☒ |
|  | Emerging Growth Company&nbsp;&nbsp;&nbsp;&nbsp; ☐ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; No ☒

The number of shares of the registrant's common stock, $0.01 par value, outstanding as of August 13, 2025 was 21,409,924.

------

[**Table of Contents**](#toc)

**Table of Contents**

---

| | | |
|:---|:---|:---|
| [**PART I - FINANCIAL INFORMATION**](#part1) | [**PART I - FINANCIAL INFORMATION**](#part1) | [3](#part1) |
| &nbsp;&nbsp;&nbsp;[Item 1.](#item1) | [Financial Statements](#item1) | [3](#item1) |
| &nbsp;&nbsp;&nbsp;[Item 2.](#mda) | [Management Discussion and Analysis of Financial Condition and Results of Operations.](#mda) | [17](#mda) |
| &nbsp;&nbsp;&nbsp;[Item 3.](#item3) | [Quantitative and Qualitative Disclosures About Market Risk.](#item3) | [21](#item3) |
| &nbsp;&nbsp;&nbsp;[Item 4.](#item4) | [Controls and Procedures](#item4) | [21](#item4) |
| [**PART II** – **OTHER INFORMATION**](#part2) | [**PART II** – **OTHER INFORMATION**](#part2) | [23](#part2) |
| &nbsp;&nbsp;&nbsp;[Item 1.](#legal) | [Legal Proceedings](#legal) | [23](#legal) |
| &nbsp;&nbsp;&nbsp;[Item 2. Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity Securities Unregistered Sales of Equity Securities and Use of Proceeds](#unregistered) | &nbsp;&nbsp;&nbsp;[Item 2. Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity Securities Unregistered Sales of Equity Securities and Use of Proceeds](#unregistered) | [23](#unregistered) |
| &nbsp;&nbsp;&nbsp;[Item 3.](#defaults) | [Defaults Upon Senior Securities](#defaults) | [24](#defaults) |
| &nbsp;&nbsp;&nbsp;[Item 4.](#submission) | [Submission of Matters to a Vote of Security Holders](#submission) | [24](#submission) |
| &nbsp;&nbsp;&nbsp;[Item 5.](#other) | [Other Information](#other) | [24](#other) |
| &nbsp;&nbsp;&nbsp;[Item 6.](#exhibits) | [Exhibits](#exhibits) | [24](#exhibits) |
| [**SIGNATURES**](#signatures) | [**SIGNATURES**](#signatures) | [25](#signatures) |

---

------

[**Table of Contents**](#toc)

**<u>PART I - FINANCIAL INFORMATION</u>**

**Item 1. Financial Statements**

**ELITE HEALTH SYSTEMS INC. AND SUBSIDIARIES**

**CONSOLIDATED BALANCE SHEETS**

---

| | | |
|:---|:---|:---|
|  | **June 30,** | **December 31,** |
|  | **2025** | **2024** |
|  | **(Unaudited)** | **(Audited)** |
| **ASSETS** |  |  |
| Current assets: |  |  |
| Cash and cash equivalents | $**3121000** | $**4034000** |
| Other current assets | **40000** | **28000** |
| Due from related parties | **1000** | **12000** |
| Stock subscriptions receivable | **-** | **175000** |
| Total current assets | **3162000** | **4249000** |
| Property and equipment: |  |  |
| Capitalized software under development | **767000** | **-** |
| Operating lease right-of-use asset | **55000** | **72000** |
| Total property and equipment | **822000** | **72000** |
| **TOTAL ASSETS** | $**3984000** | $**4321000** |
| **LIABILITIES** |  |  |
| Current liabilities: |  |  |
| Operating lease right-of-use liability - current portion | $**36000** | $**34000** |
| Accounts payable and accrued expenses | **131000** | **60000** |
| Total current liabilities | **167000** | **94000** |
| Operating lease right-of-use liability - net of current portion | **19000** | **38000** |
| Guarantee liability | **11000** | **11000** |
| Total liabilities | **197000** | **143000** |
| **EQUITY** |  |  |
| Common stock - par value $.01; 25,000,000 shares authorized; 21,409,924 and 19,984,924 shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively. | **214000** | **200000** |
| Stock to be issued | **-** | **238000** |
| Additional paid-in capital | **8883000** | **8185000** |
| Accumulated deficit | **(5310000)** | **(4445000)** |
| Total stockholders' equity | **3787000** | **4178000** |
| **TOTAL LIABILITIES AND EQUITY** | $**3984000** | $**4321000** |

---

See accompanying notes to the consolidated financial statements

------

[**Table of Contents**](#toc)

**ELITE HEALTH SYSTEMS INC. AND SUBSIDIARIES**

**CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS**

**(UNAUDITED)**

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** |
|  | **June 30,** | **June 30,** |
|  | **2025** | **2024** |
| Revenue | $**-** | $**-** |
| Costs and expenses: |  |  |
| Selling, general and administrative | **445000** | **437000** |
| Total expense | **445000** | **437000** |
| Operating Income (loss) | **(445000)** | **(437000)** |
| Total other income (expense) |  |  |
| Interest income (expense) | **4000** | **-** |
| Income (loss) from investments in unconsolidated entities, net | **-** | **2000** |
| Total other (expense) | **4000** | **2000** |
| Income (loss) before income taxes | **(441000)** | **(435000)** |
| Reversal of provision for income taxes |  | **-** |
| Net Income (loss) | **(441000)** | **(435000)** |
| Net income (loss) attributable to noncontrolling interests | **-** | **-** |
| Net income (loss) attributable to Elite Health Systems Inc. | $**(441000)** | $**(435000)** |
| Basic and diluted net income (loss) per share attributable to Elite Health Systems Inc | $**(0.02)** | $**(0.03)** |
| Weighted average common shares outstanding, basic and diluted | **21409924** | **13484924** |

---

The accompanying notes to condensed consolidated financial statements are an integral part hereof.

------

[**Table of Contents**](#toc)

**ELITE HEALTH SYSTEMS INC. AND SUBSIDIARIES**

**CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS**

**(UNAUDITED)**

---

| | | |
|:---|:---|:---|
|  | **Six Months Ended** | **Six Months Ended** |
|  | **June 30,** | **June 30,** |
|  | **2025** | **2024** |
| Revenue | $**-** | $**-** |
| Costs and expenses: |  |  |
| Selling, general and administrative | **872000** | **913000** |
| Total expense | **872000** | **913000** |
| Operating Income (loss) | **(872000)** | **(913000)** |
| Total other income (expense) |  |  |
| Interest income (expense) | **7000** | **(1000)** |
| Income (loss) from investments in unconsolidated entities, net | **-** | **4000** |
| Total other (expense) | **7000** | **3000** |
| Income (loss) before income taxes | **(865000)** | **(910000)** |
| Reversal of provision for income taxes |  | **163000** |
| Net Income (loss) | **(865000)** | **(747000)** |
| Net income (loss) attributable to noncontrolling interests | **-** | **-** |
| Net income (loss) attributable to Elite Health Systems Inc. | $**(865000)** | $**(747000)** |
| Basic and diluted net income (loss) per share attributable to Elite Health Systems Inc | $**(0.04)** | $**(0.06)** |
| Weighted average common shares outstanding, basic and diluted | **21246941** | **12692067** |

---

The accompanying notes to condensed consolidated financial statements are an integral part hereof.

------

[**Table of Contents**](#toc)

**ELITE HEALTH SYSTEMS INC. AND SUBSIDIARIES**

**CONSOLIDATED STATEMENTS OF EQUITY**

**(UNAUDITED)**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  |  |  | Additional |  | Accumulated | Total |
|  | Common Stock | Common Stock | Paid-In | Stock to | Deficit | Stockholders' |
|  | Shares | Amount | Capital | Be Issued | Gain(Loss) | Equity |
| Balance, December 31, 2023 | 9284924 | $93000 | $2942000 |  | $(2390000) | $645000 |
| Net loss for the quarter ended March 31, 2024 |  |  |  |  | (312000) | (312000) |
| Balance, March 31, 2024 | 9284924 | $93000 | $2942000 |  | $(2702000) | $333000 |
| Issuance of common stock | 4200000 | 42000 | 2058000 |  |  | 2100000 |
| Net loss for the quarter ended June 30, 2024 |  |  |  |  | (435000) | (435000) |
| Balance June 30, 3024 | 13484924 | $135000 | $5000000 |  | $(3137000) | $1998000 |
| Balance, December 31, 2024 | 19984924 | $200000 | $8185000 | 238000 | $(4445000) | $4178000 |
| Issued from prior period |  |  |  | (238000) |  | (238000) |
| Issuance of common stock | 1425000 | 14000 | 698000 |  |  | 712000 |
| Net loss for the quarter ended March 31, 2025 |  |  |  |  | (424000) | (424000) |
| Balance, March 31, 2025 | 21409924 | $214000 | $8883000 |  | $(4869000) | $4228000 |
| Net loss for the quarter ended June 30, 2025 |  |  |  |  | (441000) | (441000) |
| Balance, June 30, 2025 | 21409924 | $214000 | $8883000 |  | $(5310000) | $3787000 |

---

See accompanying notes to the consolidated financial statements

------

[**Table of Contents**](#toc)

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**ELITE HEALTH SYSTEMS INC. AND SUBSIDIARIES**

**CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS**

**(UNAUDITED)**

---

| | | |
|:---|:---|:---|
|  | **Six Months Ended**  | **Six Months Ended**  |
|  | **June 30,** | **June 30,** |
|  | **2025** | **2024** |
| **Cash flows from operating activities:** |  |  |
| Net Loss | $**(865000)** | $**(747000)** |
| Adjustments to reconcile net loss to net cash used in operating activities: |  |  |
| Amortization of operating lease right-of-use asset | **17000** | **11000** |
| Income from investments in unconsolidated entities, net | **-** | **(4000)** |
| Changes in: |  |  |
| Income taxes payable | **-** | **(166000)** |
| Other current assets | **(12000)** | **15000** |
| Stock subscription receivable | **175000** | **-** |
| Accounts payable and accrued expenses | **71000** | **(11000)** |
| Operating lease right-of-use liability | **(17000)** | **(10000)** |
| Advances to unconsolidated entities |  | **(4000)** |
| Net cash provided by (used in) operating activities | **(631000)** | **(916000)** |
| **Cash flows from investing activities:** |  |  |
| Receipt of distributions outstanding | **11000** | **-** |
| Capitalization of software development costs | **(767000)** |  |
| Net cash provided by (used in) investing activities | **(756000)** | **-** |
| **Cash flows from financing activities:** |  |  |
| Sale of shares | **460000** | **545000** |
| Issuance of common stock | **14000** | **2100000** |
| Net cash provided by (used in) financing activities | **474000** | **2645000** |
| **Net change in cash and cash equivalents** | **(913000)** | **1729000** |
| Cash and cash equivalents - beginning of period | **4034000** | **466000** |
| **Cash and cash equivalents - end of period** | $**3121000** | $**2195000** |

---

The accompanying notes to condensed consolidated financial statements are an integral part hereof

------

[**Table of Contents**](#toc)

**<u>Note A - Basis of Preparation</u>**

**Organization and Business**

Elite Health Systems Inc., formerly U.S. NeuroSurgical Holdings, Inc. through its wholly-owned subsidiaries, is developing a business to provide Medicare Advantage plans and related services, concentrating initially in California and Nevada. As used herein, unless the context indicates otherwise, the term "Company" and "Registrant" means Elite Health Systems Inc. and its wholly-owned subsidiary, Elite Health Systems Holdings Inc. ("EHSH"), and the wholly-owned subsidiaries of EHSH, U.S. NeuroSurgical Physics, Inc., USN Corona, Inc., Elite Health Plan, Inc. and Elite Health Plan of Nevada, Inc.

**Company Background.**

The Company was previously engaged in the ownership and operations of radiation treatment centers. Most of these businesses have been sold or wound down, and the Company has been actively pursuing opportunities to expand to other businesses that could benefit its current operations and relationships. Effective October 1, 2021, the Company acquired all of the outstanding shares of capital stock of Elite Health Plan, Inc., a California corporation ("EHP"), and, in exchange therefor, the former holders of Elite Health were issued newly-issued shares of EHSH, which following the transaction represented 15% of the outstanding shares of EHSH. Effective November 27, 2023, the Company entered into a Share Exchange Agreement with the holders of these minority interests in EHSH, which resulted in making EHSH's wholly-owned subsidiary of the Company and the former minority holders of EHSH 15% owners of the Company immediately following the exchange. As a result of the November 27, 2023 transaction,1,392,739 shares of the Company's common stock were issued, bringing the total outstanding to 9,284,924 shares as of that date. Since that time, the Company raised an additional $5,825,000 through the private sale of 11,650,000 shares of common stock and in addition to 475,000 shares issued as compensation to certain officers and directors, bringing the total outstanding to 21,409,924 shares as of June 30, 2025.

The Company has determined that its best opportunity for long term success is to concentrate its efforts and resources on establishing a managed care organization that will develop and operate Medicare Advantage plans for, and provide related health services to, seniors in California and other areas in the U.S., and could pursue growth through other commercial opportunities and strategic transactions, including partnerships, acquisitions or mergers related and complementary to these activities and services.

------

[**Table of Contents**](#toc)

In furtherance of this plan, EHP filed for and was awarded a Knox-Keene license to offer managed health care plans in California in May 2025. In June 2025, EHP was notified by the Centers for Medicare and Medicaid Services ("CMS") that it has conditionally approved EHP's contract year (CY) 2026 Medicare Advantage/Medicare – Prescription Drug (MA-Only/MA-PD) application. In addition, EHSH recently formed Elite Health Plan of Nevada, Inc. to apply for a license to operate a Medicare Advantage plan in Nevada. EHP and Elite Health Plan of Nevada, Inc., both 100% owned by EHSH and managed and operated in a similar manner, are collectively referred to herein as "Elite Health." In California, Elite Health has taken preliminary steps toward identifying a network of providers who are well-versed in Medicare Advantage plans and addressing the healthcare needs of seniors in the communities in which they practice. Elite Health currently has no revenue, and will not be in a position to generate significant revenue until it obtains final approval from CMS to operate a Medicare Advantage plan in California. The success of Elite Health will depend, in part, on obtaining in a timely manner all necessary approvals and gaining access to a sufficient network of providers and enrolling a critical level of subscribers. There can be no assurance that the Company and Elite Health will be successful in obtaining the necessary approvals to operate Medicare Advantage plans in any jurisdiction or be effective in establishing the network of providers and developing the systems required to operate a managed care business.

Until January 2024, the Company's executive offices were located at 2400 Research Boulevard, Suite 325, Rockville, MD 20850. The Company's headquarters are now located at 1131 W 6<sup>th</sup> Street, Suite 225, Ontario, CA 91762 and its telephone number is (949) 249-1170.

<u>Recent Accounting Pronouncements</u>

*FASB ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures*

The FASB issued ASU 2023-07 on November 27, 2023, which is intended to improve reportable segment disclosure requirements. Under previous guidance, while entities were required to disclose segment revenue and measure of profit or loss, there has been limited disclosure around the reporting of segment expenses. In addition to enhanced disclosures about significant segment expenses, the amendments enhance interim disclosure requirements, clarify circumstances in which an entity can disclose multiple segment measures of profit or loss, provide new segment disclosure requirements for entities with a single reportable segment, and contain other disclosure requirements. The purpose of the amendments is to enable investors to better understand an entity's overall performance and assess potential future cash flows. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. The Company has adopted the requirements of the expanded segment disclosures as of December 31, 2024.

The Company applies the provisions of Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") *Topic 810, Consolidation* to noncontrolling interests in consolidated financial statements. The guidance requires noncontrolling interests to be reported as a component of equity separate from the parent's equity and purchases and sales of equity interests, that do not result in a change in control, to be accounted for as equity transactions. In addition, net (loss) income attributable to noncontrolling interests are to be included in net (loss) income and, upon a loss of control, the interest sold, as well as any interest retained, is to be recorded at fair value, with any gain or loss recognized in net (loss) income.

All amounts are shown in nearest thousands in the Consolidated Financial Statements and accompanying notes therein.

------

[**Table of Contents**](#toc)

<u>Liquidity and Going Concern</u>

In fiscal year 2024, the Company incurred a net loss of $2,055,000 compared to $816,000 in fiscal year 2023. The Company has received conditional state and Federal approval to operate as a Medicare Advantage plan and is in the development stage of preparing to operate. As a result, it has no revenue and significant expenses. The Company has funded operations through the sale of common stock. The Company recorded a losses of $865,000 and $747,000 during the six months ended June 30, 2025 and 2024, respectively, had an accumulated deficit in stockholders' equity of $5,310,000 and $4,445,000 at June 30, 2025 and December 31, 2024, respectively; cash and cash equivalents of $3,121,000 and $4,034,000 at June 30, 2025 and December 31, 2024, respectively; and working capital of $2,995,000 and $4,155,000 at June 30, 2025 and December 31, 2024, respectively. In addition, the Company currently does not have access to capital through a line of credit nor other readily available sources of capital. Together, these factors raised substantial doubt regarding the Company's ability to continue as a going concern at June 30, 2025. The Company raised an additional $5,825,000 through the private sale of 11,650,000 shares of common stock and in addition to 475,000 shares issued as compensation to certain officers and directors, bringing the total outstanding to 21,409,924 shares as of June 30, 2025 and 19,984,924 at December 31, 2024. In July 2025, The Company announced plans to commence a private placement of shares of the Company's common stock for expected proceeds of a minimum of $2,000,000 and up to a maximum of $5,000.000 at a price of $0.95 per share.

However, management has considered its plans to continue the Company as a going concern, concentrating on the establishment and operation of managed health care plans. The Company raised gross proceeds of approximately $5.8 million in support of this business opportunity through the sale of its common stock in a private placement and believes it will be successful in raising additional capital in 2025. Additionally, the Company believes that these activities and resulting expenses can be managed to the level of cash resources on hand and expected to be raised. Management believes its plan alleviates the substantial doubt and that it will be successful in its planned business initiatives and will be able to continue as a going concern through at least the next twelve months. However, there can be no assurance that sources of capital will be available to the Company at that time or, if available, can be obtained on terms favorable to the Company.

Pursuant to accounting requirements of the Securities and Exchange Commission applicable to quarterly reports on Form 10-Q, the accompanying Condensed Consolidated Financial Statements and notes do not include all disclosures required by accounting principles generally accepted in the United States of America for complete financial statements. Accordingly, these statements should be read in conjunction with the Company's most recent annual Consolidated Financial Statements.

Consolidated results of operations for interim periods are not necessarily indicative of those to be achieved for full fiscal years. The only change to the Company's equity in the three months ended June 30, 2025 and 2024 was net loss for the periods and issuance of common stock.

------

[**Table of Contents**](#toc)

The Company applies the provisions of Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") *Topic 810, Consolidation* to noncontrolling interests in consolidated financial statements. The guidance requires noncontrolling interests to be reported as a component of equity separate from the parent's equity and purchases and sales of equity interests, that do not result in a change in control, to be accounted for as equity transactions. In addition, net (loss) income attributable to noncontrolling interests are to be included in net (loss) income and, upon a loss of control, the interest sold, as well as any interest retained, is to be recorded at fair value, with any gain or loss recognized in net (loss) income.

The Company recognizes revenue in accordance with two different accounting standards: 1) Topic 606 and 2) Accounting Standards Codification ("ASC") Topic 842, *Leases*. However, the Company is not currently generating revenue.

In accordance with ASC 350-40, *Internal Use Software,* the Company capitalizes certain internal use software development costs associated with creating and enhancing internally developed software related to its platforms. Software development activities generally consist of three stages (i) the research and planning stage, (ii) the application and development stage, and (iii) the post-implementation stage. Costs incurred in the planning and post-implementation stages of software development, or other maintenance and development expenses that do not meet the qualification for capitalization are expensed as incurred. Costs incurred in the application and infrastructure development stage, including significant enhancements and upgrades, are capitalized. These costs relate to services provided by a vendor that are directly associated with the software projects. Software development and acquired technology costs will be amortized on a straight-line basis over the initial term of the license agreement with the vendor through December 31, 2030.

Basic loss per share has been computed using the weighted-average number of shares of common stock outstanding during the period. The numerator for the calculation of basic and diluted earnings per share is net loss and the denominator is the weighted-average number of common shares outstanding during the period.

The tables below present financial information associated with our leases.

---

| | | | |
|:---|:---|:---|:---|
|  | **Classification** | **June 30,** | **June 30,** |
|  |  | **2025** | **2024** |
| **Assets** | **Assets** |  |  |
| Long-term | Long-term |  |  |
| Operating lease assets | Operating lease right-of-use asset | $55000 | $74000 |
| **Total leased assets** | **Total leased assets** | $55000 | $74000 |
| **Liabilities** | **Liabilities** |  |  |
| Current | Current |  |  |
| Operating lease liabilities | Operating lease right-of-use liability - current portion | $36000 | $28000 |
| Long-term | Long-term |  |  |
| Operating lease liabilities | Operating lease right-of-use liability - net of current portion | $19000 | $47000 |
| **Total lease liabilities** | **Total lease liabilities** | $55000 | $75000 |
| **Lease Cost** | **Lease Cost** |  |  |
| Operating lease cost | Selling, general and administrative | $17000 | $23000 |
| Net lease expense | Net lease expense | $17000 | $23000 |

---

---

| | |
|:---|:---|
| Maturity of lease liabilities (as of June 30, 2025) | Operating lease |
| 2025 | $19000 |
| 2026 | 38000 |
| Total | $57000 |
| Less amount representing interest | 2000 |
| Present value of lease liabilities | $55000 |
| Discount rate | 4.140% |

---

------

[**Table of Contents**](#toc)

**<u>Note B</u>**<u>–</u> **<u>Boca Oncology Partners</u>**

During the first quarter of 2011, the Company, through the formation of a joint venture, in which it had a noncontrolling interest, participated in the formation of Boca Oncology Partners, LLC ("BOP"), for the purpose of owning and operating a cancer center in Boca Raton, Florida. In June 2011, BOPRE, an affiliated entity, purchased a 20% interest in Boca West IMP, owner of a medical office building in West Boca, Florida in which BOP operates. BOP occupies 6,000 square feet of the 32,000 square foot building. The Company invested $32,000 initially and had a 22.5% interest in BOP and BOPRE. In February 2014, the Company and other members sold their interests in BOP.

In September 2024, the Company sold its interest in BOPRE to the remaining members for $1,210,840, resulting in a gain of $97,000 during the quarter ended September 30, 2024

The following tables present the summarized financial information of BOPRE:

**BOPRE Condensed Income Statement Information**

---

| | | |
|:---|:---|:---|
|  | **Six Months Ended** | **Six Months Ended** |
|  | **June 30,** | **June 30,** |
|  | **2025** | **2024** |
| Rental Income | $- | $- |
| Net income | $- | $17000 |
| EHSHI's equity in earnings of BOPRE | $- | $4000 |

---

**BOPRE Condensed Balance Sheet Information**

---

| | | |
|:---|:---|:---|
|  | **June 30,** | **December 31,** |
|  | **2025** | **2024** |
| Current assets | $- | $- |
| Noncurrent assets |  |  |
| Total assets | $- | $- |
| Current liabilities |  | $- |
| Noncurrent liabilities |  |  |
| Equity |  |  |
| Total liabilities and equity | $- | $- |

---

------

[**Table of Contents**](#toc)

**<u>Note C- CB Oncology Partners</u>**

CBOP was organized September 1, 2017, to acquire the rights of the new center from FOP. EHSHI originally had a 24% equity interest in CBOP. Beginning in October of 2017, CBOP began paying the remainder of the costs associated with opening the center. CBOP had no assets at the end of 2017. The medical center opened and treated its first patient in January of 2018.

Effective November 15, 2019, FOP transferred to, and CBOP assumed, a loan with BB&T bank, that it had entered in order to finance the purchase of equipment and build out of the new center, as well as the associated property and equipment. In addition, CBOP and BB&T agreed to reduce the monthly loan repayments for the next nine months, and to extend the term of the loan from November 2024 to July 2025. In July 2020 CBOP and BB&T further agreed to reduce the monthly payments for the life of the loan and extended the loan to July of 2027.

In June 2020, CBOP made a $500,000 capital call to its members. UNSC converted previously made advances totaling $121,000 into equity in CBOP to meet its capital requirement, and other members contributed $212,000 in cash. The remaining capital contributions are not expected to be met and, accordingly, the Company's equity interest in CBOP increased to 28.58% in June 2020.

During the year ended December 31, 2024, the Company did not lend any additional funds to CBOP. During the year ended December 31, 2023, the Company advanced $535,000, less $21,000 which was repaid by CBOP for a net receivable of $519,000. In addition, CBOP made a $200,000 capital call to its members resulting in an equity contribution from the Company of $57,000. This equity investment was fully impaired due to Equity Method accounting. These allowances and write-offs were recorded as losses from investments in unconsolidated entities. For the years ended December 31, 2024 and 2023, the Company's equity in loss of CBOP was $278,000 and $444,000, respectively, but was not recorded due to prior losses.

Due to loans made to CBOP, CBOP is considered to be a variable interest entity of the Company. However, as the Company is not deemed to be the primary beneficiary of CBOP, since it does not have the power to direct the operating activities that most significantly affect CBOP's economic performance, the entity is not consolidated, but certain disclosures are provided herein.

In June, 2025 the Company agreed to relinquish its ownership interest in CBOP to Dr. Jaime Lozano upon receipt of evidence that Dr. Lozano retired certain debt of CBOP for which the Company is contingently liable. The agreement is null and void if Dr. Lozano fails to pay off the loan within 120 days of the acceptance of the agreement. The Company does not expect any further returns from, or liability exposure relating to, CBOP.

------

[**Table of Contents**](#toc)

The following table presents the summarized financial information of CBOP:

**CBOP Condensed Income Statement Information**

---

| | | |
|:---|:---|:---|
|  | **Six Months Ended** | **Six Months Ended** |
|  | **June 30,** | **June 30,** |
|  | **2025** | **2024** |
| Patient revenue | $696000 | $584000 |
| Net (loss) income | $(456000) | $(761000) |
| EHSHI's equity in (loss) income of CBOP | $(109000) | $(230000) |

---

**CBOP Condensed Balance Sheet Information**

---

| | | |
|:---|:---|:---|
|  | **June 30,** | **December 31,** |
|  | **2025** | **2024** |
| Current assets | $202000 | $347000 |
| Noncurrent assets | 1486000 | 1785000 |
| Total assets | $1688000 | $2132000 |
| Current liabilities | $4291000 | $4067000 |
| Noncurrent liabilities | 3359000 | 3572000 |
| Deficit | (5962000) | (5507000) |
| Total liabilities and stockholder's deficit | $1688000 | $2132000 |

---

------

[**Table of Contents**](#toc)

**<u>Note D</u>** <u>–</u> **<u>Elite Health</u>**

<u>Background</u>. Elite Health Plan, Inc. was formed in 2017 with the purpose of establishing a managed care organization that will develop and operate Medicare Advantage plans for seniors in California. In addition to pursuing the required authorizations, including a Knox-Keene license from California's Department of Managed Health Care ("DMHC"), necessary for the operation of full service health plans in California, and approval from the Centers for Medicare & Medicaid Services ("CMS"), the Company is considering engaging in related businesses and health services to support this mission.

Medicare Advantage plans are offered by private companies and are regulated by the federal government and licensed by the state in which those companies operate. Once it receives full approval, Elite Health expects to initially operate in the California counties of San Bernadino, Riverside, and Los Angeles, with the objective of addressing the growing number of Medicare eligible seniors in those markets. The Company then expects to apply to the State of Nevada and begin operations in Clark County, Nevada. Because of the collective experience of its founders and affiliates as physicians, software executives, and health plan administrators, we believe that Elite Health will be positioned to bring to California and Nevada a comprehensive, community-based and cost-effective health care management service solution for these communities.

<u>Filing in California</u>. The Company initially applied for a license to operate a Medicare Advantage plan in Nevada. However, the Company determined that a reciprocity agreement between California and Nevada would result in a more expedient path to licensing in Nevada would be to secure approvals in California first. For this reason, Elite Health is focused its efforts on completing the process toward obtaining a Knox-Keene license in California, and securing necessary approvals from CMS. It received the required approval from California, conditional approval from CMS and is awaiting CMS approval of its bid submission. There can be no assurance that necessary approvals will be obtained or, if obtained, this will be accomplished in a timely manner.

**<u>Note E</u>** <u>–</u> **<u>Internal Use Software</u>**

In accordance with ASC 350-40, *Internal Use Software,* the Company capitalizes certain internal use software development costs associated with creating and enhancing internally developed software related to its platforms. Software development activities generally consist of three stages (i) the research and planning stage, (ii) the application and development stage, and (iii) the post-implementation stage. Costs incurred in the planning and post-implementation stages of software development, or other maintenance and development expenses that do not meet the qualification for capitalization are expensed as incurred. Costs incurred in the application and infrastructure development stage, including significant enhancements and upgrades, are capitalized. These costs relate to services provided by a vendor that are directly associated with the software projects. These software development and acquired technology costs will be amortized on a straight-line basis over the initial term of the license agreement with the vendor through December 31, 2030.

------

[**Table of Contents**](#toc)

**<u>Note F</u>** <u>–</u> **<u>Income Taxes</u>**

The Company's income tax rate, which includes federal and state income taxes, was 0%, for each of the three months ended June 30, 2025, and 2024, respectively.

**<u>Note G</u>** <u>–</u> **<u>Segment Reporting</u>**

The Company applies ASC 280, Segment Reporting, in determining reportable segments for its financial statement disclosure. Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the Chief Operating Decision Maker ("CODM") in deciding how to allocate resources to an individual segment and in assessing performance. The Company's CODM is its Chief Executive Officer ("CEO"). The Company has determined that it operates as a single operating segment and has one reportable segment."

**<u>Note H</u>** <u>–</u> **<u>Transactions with Related Parties</u>**

The Company recorded compensation with directors and officers of the Company for the year ended December 31, 2024 consisting of stock grants valued at $0.50 per share of 75,000 for each of directors St. Lawrence and Leimkuhler; 75,000 for our Executive Director and 250,000 for CEO and Board Chair, Dr. Jeereddi. Such shares were issued in January 2025. Additionally, the Company compensates Physician Support Systems, Inc. ("PSS") for services of Executive Director and others as well as the sharing of rental space and other services. Dr. Jeereddi is the majority owner of PSS and our Executive Director is an employee.

**<u>Note I</u>** <u>–</u> **<u>Line of Credit</u>**

On April 25, 2025 the Company's subsidiary, Elite Health Plan, Inc. ("Plan") entered into a Note and Line of Credit with Rao R. Yalamanchili ("Lender") for $2,500,000, the ("LOC"). The LOC is available to be drawn in the future, in whole or in part, to aid Plan in meeting the tangible net equity requirements of the State of California, Department of Managed Health Care for licensure as a health care service plan. Simultaneously with execution of the note, Plan entered into a Subordination Agreement that subordinates the rights of Lender to all present and future creditors of Plan. There is no outstanding balance under the LOC.

**<u>Note J</u>** <u>–</u> **<u>Subsequent Events</u>**

In July, 2025 the Company commenced a private placement of shares of the Company's common stock for expected proceeds of a minimum of $2,000,000 and up to a maximum of $5,000,000 at a price per share of $0.95.

In July, 2025, the Company also announced that it had entered into a non-binding letter of intent to acquire all the outstanding shares of PSS in exchange for 3,158,000 shares of the Company's common stock. Dr. Prasad Jeereddi, the Company's Chief Executive Officer, owns 51% of PSS and Dr. Praveena Jeereddi (Dr. Prasad Jeereddi's daughter) owns 49% of PSS. The completion of the PSS transaction is subject to and contingent on a number of factors including: (i) satisfactory completion of due diligence by the Company, (ii) execution of the definitive Acquisition Agreement by the Company and the selling stockholders of PSS, and (iii) the approval by the Company stockholders of the Acquisition Agreement as well as an increase in the authorized common stock of the Company.

------

[**Table of Contents**](#toc)

In August, 2025 the Board approved the establishment of an equity incentive plan with a maximum number of shares issuable pursuant to the plan of 4,500,000. The plan is subject to approval by the Company's stockholders and approval of an increase in the maximum number of shares authorized for issuance.

**Item 2. Management Discussion and Analysis of Financial Condition and Results of Operations.**

<u>Critical Accounting Policies</u>

The Condensed Consolidated Financial Statements of Elite Health Systems Inc. and subsidiaries (the "Company") have been prepared in accordance with accounting principles generally accepted in the United States of America. As such, some accounting policies have a significant impact on amounts reported in the Condensed Consolidated Financial Statements. A summary of those significant accounting policies can be found in Note B to the Consolidated Financial Statements, in our 2024 Annual Report on Form 10-K. In particular, judgment is used in areas such as determining and assessing possible asset impairments, including investments in, and advances, to unconsolidated entities.

The following discussion and analysis provides information which the Company's management believes is relevant to an assessment and understanding of the Company's results of operations and financial condition. This discussion should be read in conjunction with the Condensed Consolidated Financial Statements and notes thereto appearing elsewhere herein.

<u>Recent events</u>

None

<u>Results of Operations</u>

*Three months ended June 30, 2025, Compared to Three Months Ended June 30, 2024*

Selling, general, and administrative expenses of $444,000 for the second quarter of 2025 were 2% higher than the $437,000 incurred during the comparable period in 2024, due mostly to the start-up costs for Elite Health Plan.

During the three months ended June 30, 2025, the Company recognized no gain or loss from its investment in unconsolidated entities compared to $2,000 gain during the same period in 2024.

------

[**Table of Contents**](#toc)

During the three months ended June 30, 2025 and 2024, the Company recorded no income tax benefit or provision.

For the three months ended June 30, 2025, the Company reported a net loss of $441,000 as compared to $435,000 for the same period a year earlier. The net loss was primarily due to investment in Elite prior to generation of any revenue.

*Six months ended June 30, 2025, Compared to Six Months Ended June 30, 2024*

Selling, general, and administrative expenses of $872,000 for the first six months of 2025 were 4% lower than the $913,000 incurred during the comparable period in 2024, due mostly to the start-up costs for Elite Health Plan.

During the six months ended June 30, 2025 and 2024, the Company recognized $0 and $4,000 gain from its investment in unconsolidated entities, respectively.

During the six months ended June 30, 2025 and 2024, the Company recorded no income tax benefit or provision.

For the six months ended June 30, 2025, the Company reported a net loss of $865,000 as compared to $747,000 for the same period a year earlier. The net loss was primarily due to investment in Elite prior to generation of any revenue.

<u>Liquidity and Capital Resources</u> 

The Company's primary sources of liquidity are from equity transactions discussed below.

Net cash used in operating activities for the six months ended June 30, 2025, was $691,000 as compared to $916,000 for the same period a year earlier. This change is primarily due to the Company using cash to invest in the Elite business. During the six months ended June 30, 2025 and 2024, the Company received $0 of distributed earnings from unconsolidated entities

On January 16, 2024, the Company held an initial closing of a private placement of shares of the Company's common stock to raise gross proceeds of not less than $1,000,000, and up to $2,000,000, at a price of $0.50 per share. Since the initial closing, the Company amended the terms of the private placement to raise up to $5,500,000 and raised total proceeds of an aggregate of $5.8 million. As a result of these issuances, as of June 30, 2025, there were outstanding 21,409,924 shares of the Company's common stock.

In July 2025, The Company announced plans to commence a private placement of shares of the Company's common stock for expected proceeds of a minimum of $2,000,000 and up to a maximum of $5,000,000 at a price of $0.95 per share.

------

[**Table of Contents**](#toc)

For this sale of securities in connection with private placement, no general solicitation was used, no commissions were paid, all participants in the private placement were accredited investors, and the Company relied on the exemption from registration available under Section 4(a)(2) and/or Rule 506(b) of Regulation D promulgated under the Securities Act with respect to transactions by an issuer not involving any public offering.

The Company presently intends to use the net proceeds from the private placement principally to execute the plan of Elite Health to establish a managed care organization that will operate as a Medicare Advantage plan for seniors.

The Company presently intends to use the net proceeds from the private placement principally to execute the plan of Elite Health to establish a managed care organization that will operate as a Medicare Advantage plan for seniors.

In fiscal year 2024, the Company incurred a net loss of $2,055,000 compared to $816,000 in fiscal year 2023. The Company has received conditional state and Federal approval to operate as a Medicare Advantage plan and is in the development stage of preparing to operate. As a result, it has no revenue and significant expenses. The Company has funded operations through the sale of common stock. The Company recorded a losses of $865,000 and $747,000 during the six months ended June 30, 2025 and 2024, respectively, had an accumulated deficit in stockholders' equity of $5,310,000 and $4,445,000 at June 30, 2025 and December 31, 2024, respectively; cash and cash equivalents of $3,121,000 and $4,034,000 at June 30, 2025 and December 31, 2024, respectively; and working capital of $2,995,000 and $4,155,000 at June 30, 2025 and December 31, 2024, respectively. In addition, the Company currently does not have access to capital through a line of credit nor other readily available sources of capital. Together, these factors raised substantial doubt regarding the Company's ability to continue as a going concern at June 30, 2025. The Company raised an additional $5,825,000 through the private sale of 11,650,000 shares of common stock and in addition to 475,000 shares issued as compensation to certain officers and directors, bringing the total outstanding to 21,409,924 shares as of June 30, 2025 and 19,984,924 at December 31, 2024. In July 2025, The Company announced plans to commence a private placement of shares of the Company's common stock for expected proceeds of a minimum of $2,000,000 and up to a maximum of $5,000.000 at a price of $0.95 per share.

However, management has considered its plans to continue the Company as a going concern, concentrating on the establishment and operation of managed health care plans. The Company raised gross proceeds of approximately $5.8 million in support of this business opportunity through the sale of its common stock in a private placement and believes it will be successful in raising additional capital in 2025. Additionally, the Company believes that these activities and resulting expenses can be managed to the level of cash resources on hand and expected to be raised. Management believes its plan alleviates the substantial doubt and that it will be successful in its planned business initiatives and will be able to continue as a going concern through at least the next twelve months. However, there can be no assurance that sources of capital will be available to the Company at that time or, if available, can be obtained on terms favorable to the Company.

------

[**Table of Contents**](#toc)

<u>Risk Factors</u> 

We desire to take advantage of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. The factors listed under the caption "Risk Factors" in Annual Report on our Form 10-K for the fiscal year ended December 31, 2024, have affected or could affect our actual results and could cause such results to differ materially from those expressed in any forward-looking statements made by us. Investors should carefully consider these risks and speculative factors inherent in and affecting our business and an investment in our common stock.

<u>Disclosure Regarding Forward Looking Statements</u>

The Securities and Exchange Commission encourages companies to disclose forward looking information so that investors can better understand a company's future prospects and make informed investment decisions. This document contains such "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, particularly statements anticipating future growth in revenues and cash flow. Words such as "anticipates," "estimates," "expects," "projects," "targets," "intends," "plans," "believes," "will be," "will continue," "will likely result," and words and terms of similar substance used in connection with any discussion of future operating or financial performance identify such forward-looking statements. Those forward-looking statements are based on management's present expectations about future events. As with any projection or forecast, they are inherently susceptible to uncertainty and changes in circumstances, and the Company is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements whether as a result of such changes, new information, future events or otherwise.

The Company operates in a highly competitive and rapidly changing environment and in businesses that are dependent on our ability to: achieve profitability; increase revenues; sustain our current level of operations; maintain satisfactory relations with business partners; attract and retain key personnel; maintain and expand our strategic alliances; and protect our intellectual property. The Company's actual results could differ materially from management's expectations because of changes in such factors. New risk factors can arise and it is not possible for management to predict all such risk factors, nor can it assess the impact of all such risk factors on the Company's business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, investors should not place undue reliance on forward-looking statements as a prediction of actual results. Factors that could cause actual results to differ materially from those currently anticipated include the following:

● Uncertainties relating to our ability to successfully implement our strategy of developing a Medicare Advantage plan under our Elite Health subsidiaries;

● Uncertainty over our ability to all approvals relating to a Medicare Advantage license in California in a timely manner, acquire managed health consumers in California, secure appropriate licensing and expand consumer enrollment beyond this initial state, or diversify and expand our portfolio of products and services, our business and results of operations will be significantly impaired;

● Our ability to raise capital in the future on satisfactory terms;

● Our financial condition and liquidity;

------

[**Table of Contents**](#toc)

● Uncertainty over our ability to successfully implement management's plan to improve liquidity, including the ability to manage costs, systems and growth;

All forward looking statements should be considered in the context of the risks and other factors described above and in "Risk Factors" (Part I, Item 1A of the Company's Annual Report on Form 10-K for the Fiscal Year ended December 31, 2024), "Quantitative and Qualitative Disclosures about Market Risk" (Part II, Item 7A of the Company's Annual Report on Form 10-K for the Fiscal Year ended December 31, 2024), and "Management's Discussion and Analysis" (Part I, Item 2 of this Form 10-Q). We undertake no obligation to update or revise publicly any forward-looking statements, whether because of new information, future events, or otherwise.

Investors should also be aware that while the Company might, from time to time, communicate with securities analysts, it is against the Company's policy to disclose to them any material non-public information or other confidential commercial information. Accordingly, investors should not assume that the Company agrees with any statement or report issued by any analyst irrespective of the content of the statement or report. Furthermore, the Company has a policy against issuing or confirming financial forecasts or projections issued by others. Thus, to the extent that reports issued by securities analysts or others contain any projections, forecasts or opinions, such reports are not the responsibility of the Company.

In addition, the Company's overall financial strategy, including growth in operations, maintaining financial ratios and strengthening the balance sheet, could be adversely affected by increased interest rates, construction delays or other transactions, economic slowdowns and changes in the Company's plans, strategies and intentions.

**Item 3. Quantitative and Qualitative Disclosures About Market Risk.**

Not applicable.

**Item 4. Controls and Procedures**

<u>Evaluation of Disclosure Controls and Procedures</u>

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in the Company's reports under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms, and that such information is accumulated and communicated to our management, as appropriate, to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. We do realize that we are a very small company and as a small company with only the officers and directors participating in the day to day management, with the ability to override controls, each officer and director has multiple positions and responsibilities that would normally be distributed among several employees in larger organizations with adequate segregation of duties to ensure the appropriate checks and balances.

------

[**Table of Contents**](#toc)

Our management evaluated the effectiveness of the design and operation of the Company's disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934) as of the end of the period covered by this report. Based upon that evaluation, the Company's Chief Executive Officer and Chief Financial Officer concluded that the Company's disclosure controls and procedures were effective as of the end of the period covered by this report for the information required to be disclosed by the Company in the reports it files or submits under the Securities Exchange Act of 1934, as amended, to be recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission's rules and forms, due to the material weakness in internal control over financial reporting described below.

<u>Internal Control over Financial Reporting</u>

Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934). Internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with accounting principles generally accepted in the United States of America. The Company's internal control over financial reporting includes those policies and procedures that:

(i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Company.

(ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with accounting principles generally accepted in the United States of America, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and directors of the Company.

(iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company's assets that could have a material effect on the financial statements.

Because of inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Therefore, even those systems determined to be effective can provide only reasonable assurance of achieving their control objectives.

------

[**Table of Contents**](#toc)

Our management assessed the effectiveness of the Company's internal control over financial reporting as of June 30, 2025. A material weakness is a control deficiency, or a combination of control deficiencies in internal controls over financial reporting, such that there is a reasonable possibility that a material misstatement of annual or interim financial statements will not be prevented or detected on a timely basis. In connection with the assessment described above, management identified the following material weakness as of September 30, 2024: The Company did not maintain sufficient qualified personnel with the appropriate level of knowledge, experience and training in the application of accounting principles generally accepted in the United States of America and in internal controls over financial reporting commensurate with its financial reporting requirements. Specifically, effective controls were not designed and in place to ensure that the Company maintained, or had access to, appropriate resources with adequate experience and expertise in the area of financial reporting for transactions such as investments in unconsolidated entities, related party receivables, impairments, lease accounting, accounting for business combinations, income taxes, and to properly assess the application of new accounting pronouncements. The Company brought on a consultant with experience in these matters and believes this material weakness has been remediated.

<u>Changes in Internal Control over Financial Reporting</u>

While there have not been any changes in the Company's internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the fiscal quarter ended September 30, 2024, management is in the process of developing plans to remediate the material weakness identified above.

**<u>PART II</u>** <u>–</u> **<u>OTHER INFORMATION</u>**

**Item 1. Legal Proceedings**

None

**Item 2. Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity Securities Unregistered Sales of Equity Securities and Use of Proceeds**

On January 16, 2024, the Company held an initial closing of a private placement of shares of the Company's common stock to raise gross proceeds of not less than $1,000,000, and up to $2,000,000, at a price of $0.50 per share. Since the initial closing, the Company amended the terms of the private placement to raise up to $5,500,000 and raised total proceeds of an aggregate of $5.8 million. As a result of these issuances, as of June 30, 2025, there were outstanding 21,409,924 shares of the Company's common stock.

For this sale of securities in connection with private placement, no general solicitation was used, no commissions were paid, all participants in the private placement were accredited investors, and the Company relied on the exemption from registration available under Section 4(a)(2) and/or Rule 506(b) of Regulation D promulgated under the Securities Act with respect to transactions by an issuer not involving any public offering.

------

[**Table of Contents**](#toc)

The Company presently intends to use the net proceeds from the private placement principally to execute the plan of Elite Health to establish a managed care organization that will operate as a Medicare Advantage plan for seniors.

**Item 3. Defaults Upon Senior Securities**

Not applicable.

**Item 4. Submission of Matters to a Vote of Security Holders**

Not applicable.

**Item 5. Other Information**

Not applicable.

**Item 6. Exhibits**

---

| | |
|:---|:---|
| 31.1 | [Certification of President and Chief Executive Officer (Principal Executive Officer) pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, filed herewith.](ex_850009.htm) |
| 31.2 | [Certification of Chief Financial Officer (Principal Financial Officer) pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, filed herewith.](ex_850010.htm) |
| 32.1 | [Certification of President and Chief Executive Officer (Principal Executive Officer) and Chief Financial Officer (Principal Financial Officer) pursuant to Rule 13a-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, filed herewith.](ex_850011.htm) |
| 101 | Interactive Data Files providing financial information from the Registrant's Quarterly Report on Form 10-Q for the quarter ended June 30, 2025 in iXBRL (Inline eXtensible Business Reporting Language). Pursuant to Regulation 406T of Regulation S-T, these interactive data files are deemed not filed or part of a registration statement or prospectus for purposes of Section 11 or 12 of the Securities Act of 1933, as amended, or Section 18 of the Securities Exchange Act of 1934, as amended, and are otherwise not subject to liability. |
| 104 | The Cover Page Interactive Data File, formatted in Inline XBRL (included within the Exhibit 101 attachments) |

---

------

[**Table of Contents**](#toc)

**<u>SIGNATURES</u>**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | Elite Health Systems, Inc.<br> (Registrant) | Elite Health Systems, Inc.<br> (Registrant) |
| Date: August 13, 2025 | By:  | /s/ Prasad Jeereddi |
|  |  | Prasad Jeereddi |
|  |  | Director, President and<br> Chief Executive Officer |
| Date: August 13, 2025 | By: | /s/ Kenneth Minor |
|  |  | Principal Financial and<br> Accounting Officer |

---

## Exhibit 31.1

**EXHIBIT 31.1**

**CERTIFICATION OF PRESIDENT AND CHIEF EXECUTIVE OFFICER (PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER)**

**PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, Prasad Jeereddi, certify that:

&nbsp;&nbsp;&nbsp;&nbsp;1. I have reviewed this Report on Form 10-Q of Elite Health Systems Inc.;

&nbsp;&nbsp;&nbsp;&nbsp;2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

&nbsp;&nbsp;&nbsp;&nbsp;3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

&nbsp;&nbsp;&nbsp;&nbsp;4. The registrant's other certifying officer and I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a–15(f) and 15d–15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to me by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c) Evaluated the effectiveness of the registrant's disclosure controls and procedures, and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and;

&nbsp;&nbsp;&nbsp;&nbsp;5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | |
|:---|:---|
| Date: August 13, 2025 | <u>/s/ Prasad Jeereddi</u> |
|  | Prasad Jeereddi |
|  | President & Chairman of |
|  | &nbsp;&nbsp;&nbsp;&nbsp;the Board |
|  | (Principal Executive Officer) |

---

## Exhibit 31.2

**EXHIBIT 31.2**

**CERTIFICATION OF PRESIDENT AND CHIEF EXECUTIVE OFFICER (PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER)**

**PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, Kenneth Minor, certify that:

&nbsp;&nbsp;&nbsp;&nbsp;2. I have reviewed this Report on Form 10-Q of Elite Health Systems Inc.;

&nbsp;&nbsp;&nbsp;&nbsp;3. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

&nbsp;&nbsp;&nbsp;&nbsp;4. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

&nbsp;&nbsp;&nbsp;&nbsp;5. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a–15(f) and 15d–15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to me by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c) Evaluated the effectiveness of the registrant's disclosure controls and procedures, and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and;

&nbsp;&nbsp;&nbsp;&nbsp;6. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | |
|:---|:---|
| Date: August 13, 2025 | <u>/s/ Kenneth Minor</u> |
|  | Kenneth Minor |
|  | Chief Financial Officer |
|  | (Principal Financial and<br> Accounting Officer) |

---

## Exhibit 32.1

**EXHIBIT 32.1**

**Certificate pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the**

**Sarbanes-Oxley Act of 2002**

In connection with the Quarterly Report of Elite Health Systems Inc. on Form 10-Q for the period ending June 30, 2025 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), each of the undersigned officers of Elite Health Systems Inc., certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Elite Health Systems, Inc.

<u>/s/ Prasad Jeereddi</u>

Prasad Jeereddi

President and Chief Executive Officer

(Principal Executive Officer)

<u>/s/ Kenneth Minor</u>

Kenneth Minor

Chief Financial Officer

(Principal Financial and

Accounting Officer)

Date: August 13, 2025